For decades the pharmacy go-to for musculoskeletal pain was oral paracetamol or ibuprofen. That has changed. The updated NICE guideline on osteoarthritis in over-16s (NG226) now recommends topical NSAIDs ahead of oral NSAIDs for knee osteoarthritis, and discourages reliance on paracetamol as a long-term analgesic for joint pain.
For UK community pharmacists this was one of the bigger shifts in recent counter practice. This article sets out the current evidence base, the products UK pharmacies stock, and what tends to be recommended first in 2026.
What the NICE update changed
NG226 (published 2022, reaffirmed in subsequent reviews) made three headline changes relevant to the pharmacy counter:
- Topical NSAIDs are first-line for knee osteoarthritis, and a reasonable option for hand osteoarthritis.
- Oral paracetamol should not be routinely offered for osteoarthritis unless used as a short-term top-up, because evidence for long-term effectiveness is limited.
- Oral NSAIDs should be used at the lowest effective dose for the shortest period and with attention to cardiovascular, renal and gastrointestinal risk.
The practical consequence is that a UK pharmacist now reaches for diclofenac or ibuprofen gel before suggesting a packet of tablets for a mechanical knee complaint.
Topical NSAIDs — the counter's new default
The three common UK pharmacy options are:
| Gel | Typical strength | Application | Pharmacy notes |
|---|---|---|---|
| Ibuprofen 5% | 5% gel | Up to four times a day | Widely available as own-label |
| Diclofenac 1% | 1.16% gel (Voltarol Emulgel 12h) | Twice daily | Longer duration per dose |
| Diclofenac 2.32% | Voltarol 12 Hour Joint Pain Relief | Twice daily | Higher strength, still topical |
Systemic absorption from topical NSAIDs is low — typically under 10% of an equivalent oral dose according to BNF — which is what makes them a safer first line than oral tablets. Contraindications still apply: known NSAID allergy, broken skin, severe renal or cardiac disease.
Capsaicin cream — slower, but useful for some
Capsaicin cream, derived from chilli, is available as a 0.025% OTC preparation and a higher-strength 0.075% prescription version. It works by depleting substance P in local sensory nerves. It needs to be applied three to four times daily for at least two weeks before benefit is expected, which puts a lot of patients off. Expect a burning sensation on application — this is part of the mechanism, not a side-effect.
NICE CKS on osteoarthritis lists topical capsaicin as an option, and it is sometimes the right answer for a patient who has tried topical NSAIDs without benefit or for whom NSAIDs are contraindicated.
Paracetamol — still present, but demoted
The BNF still lists paracetamol as a step-one analgesic, but NICE guidance on osteoarthritis specifically advises against routine use. For acute soft-tissue injury a short course remains reasonable. For ongoing joint pain, paracetamol is usually a top-up rather than the backbone of management.
A UK pharmacist will ask what the patient is trying to do. A two-week flare after a gardening weekend is different from five years of knee pain — and the counter recommendation will differ accordingly.
Oral NSAIDs — when the gel is not enough
If topical treatment has failed, a pharmacist may supply short-course OTC oral ibuprofen, but will check:
- Cardiovascular risk (ischaemic heart disease, recent stroke or TIA)
- Renal function concerns (diuretics, ACE inhibitors, age over 75)
- Gastrointestinal history (peptic ulcer disease, concurrent anticoagulants, SSRIs)
- Asthma triggered by NSAIDs
- Pregnancy — ibuprofen is avoided in the third trimester
For anything beyond a short OTC course, the GP takes over because of proton pump inhibitor cover and longer-term risk-benefit review.
What the pharmacy will not do
- Supply oral NSAIDs to someone on warfarin or a DOAC without GP review
- Supply high-dose or long-course oral NSAIDs at the counter
- Recommend opioid-based OTC products (co-codamol 8/500) as first-line for joint pain
- Treat suspected inflammatory arthritis — features such as morning stiffness over 30 minutes, joint swelling, or multiple joints involved should be referred to the GP for rheumatology review
How pharmacies fit the wider care pathway
In the UK, community pharmacies deal with most first-presentation musculoskeletal pain without referral, and the Pharmacy First scheme in England (which covers seven conditions) is being watched for future expansion. The PharmSee pharmacy finder can help identify a nearby pharmacy; for readers interested in the workforce behind this, the jobs data shows how busy the community sector currently is.
Caveats and sources
This article summarises current UK NICE, NHS and BNF guidance as of April 2026 and does not replace individual advice. Product strengths and application frequencies should be read from the actual pack, because formulations vary.
Sources: NICE NG226 (osteoarthritis in over 16s); NICE CKS on osteoarthritis; BNF treatment summary on analgesics; NHS patient information on osteoarthritis treatment.